- A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats
-
Chang SA, Lim BK, Lee YJ, Hong MK, Choi JO, Jeon ES
- KMID: 2155468
- J Korean Med Sci.
- 2015 May;30(5):559-568.
- doi: 10.3346/jkms.2015.30.5.559
Angiotensin receptor blockers (ARBs) have organ-protective effects in heart failure and may be also effective in doxorubicin-induced cardiomyopathy (DOX-CMP); however, the efficacy of ARBs on the prevention of DOX-CMP have... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
-
Sim DS, Jeong MH, Song HC, Kim J, Chong A, Bom HS, Jeong IS, Oh SG, Kim JM, Park DS, Kim JH, Lim KS, Kim MS, Ryu SH, Kim HK, Kim SS, Jang SY, Cho JY, Jeong HC, Lee KH, Park KH, Yoon NS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC
- KMID: 2155445
- J Korean Med Sci.
- 2015 Jan;30(1):34-43.
- doi: 10.3346/jkms.2015.30.1.34
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker (ARB), was evaluated in a porcine model of acute myocardial infarction (MI). Fifty swine were randomized to group 1 (sham, n=10),... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
-
Kim JH, Kim JM, Cho YZ, Na JH, Kim HS, Kim HA, Kang HW, Baik SK, Kwon SO, Cha SH, Kim YJ, Kim MY
- KMID: 2070256
- Clin Mol Hepatol.
- 2014 Dec;20(4):376-383.
- doi: 10.3350/cmh.2014.20.4.376
BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1
-
Jung YA, Kim HK, Bae KH, Seo HY, Kim HS, Jang BK, Jung GS, Lee IK, Kim MK, Park KG
- KMID: 2155338
- Exp Mol Med.
- 2014 Jan;46(1):e73.
- doi: 10.1038/emm.2013.143
Hepatic steatosis is common in obese individuals with hyperinsulinemia and is an important hepatic manifestation of metabolic syndrome. Sterol regulatory binding protein-1c (SREBP-1c) is a master regulator of lipogenic gene... -
- CITED
-
- Close
- SHARE
-
- Close
- The Response of Carotid Intima-Media Thickness to Medical Treatment Is Correlated with That of Intracranial Atherosclerosis
-
Kwon SU, Kim BJ, Kim SR, Kim DE, Kim HY, Lee JH, Bae HJ, Han MK, Kang DW, Kim JS, Rha JH
- KMID: 1980542
- J Clin Neurol.
- 2013 Oct;9(4):231-236.
- doi: 10.3988/jcn.2013.9.4.231
BACKGROUND AND PURPOSE: Intracranial atherosclerotic stenosis (ICAS) is considered as a major cause of stroke. The carotid intima-media thickness (CIMT), which accurately reflects the burden of generalized atherosclerosis, is also... -
- CITED
-
- Close
- SHARE
-
- Close
- Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay
-
Kim JW, Ahn I, Ryu SH, Jeon HR, Lee BS, Kim KB
- KMID: 2317838
- Toxicol Res.
- 2013 Sep;29(3):217-219.
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Fimasartan (a Novel AT1 Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats
-
Lim HJ, Lee SK, Lim DY
- KMID: 1432769
- Korean J Physiol Pharmacol.
- 2013 Feb;17(1):99-109.
- doi: 10.4196/kjpp.2013.17.1.99
The aim of this study was to determine whether fimasartan, a newly developed AT1 receptor blocker, can affect the CA release in the isolated perfused model of the adrenal medulla... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjunctive Cilostazol versus High Maintenance Dose of Clopidogrel in Patients with Hyporesponsiveness to Chronic Clopidogrel Therapy
-
Lee GY, Hahn JY, Lee SY, Kim HJ, Kim JH, Lee SY, Song YB, Choi SH, Choi JH, Gwon HC
- KMID: 1776915
- Yonsei Med J.
- 2013 Jan;54(1):34-40.
- doi: 10.3349/ymj.2013.54.1.34
PURPOSE: Whether addition of cilostazol is superior to increasing dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy is unknown. MATERIALS AND METHODS: We studied 73 patients with hyporesponsiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- Bioequivalence and Dose Proportionality of Olmesartan Medoxomil Formulations
-
Cho SK, Kim CO, Yu SH, Oh ES, Jang SB, Park YS, Cho K, Chung JY
- KMID: 2334534
- J Korean Soc Clin Pharmacol Ther.
- 2012 Dec;20(2):145-154.
BACKGROUND: Olmesartan medoxomil is an angiotensin II receptor blocker commonly used in hypertension. First objective of this study was to evaluate the bioequivalence of two olmesartan formulations, Olmesartan 20 mg... -
- CITED
-
- Close
- SHARE
-
- Close
- Spontaneous Spinal Epidural Hematoma in a Patient on Cilostazol
-
Baek SH, Lee HS, Kang JH, Shin J, Lee H, Kim I, Yang SJ, Kim JS, Shin DI, Lee SH, Lee SS
- KMID: 2288706
- Korean J Stroke.
- 2012 Dec;14(3):170-172.
Cilostazol is a phosphodiesterase inhibitor that has been shown to have similar efficacy in stroke prevention but fewer hemorrhagic events compared with aspirin. We report a case of spontaneous spinal... -
- CITED
-
- Close
- SHARE
-
- Close
- Supra-Additive Neuroprotection by Renexin, a Mixed Compound of Ginkgo Biloba Extract and Cilostazol, Against Apoptotic White Matter Changes in Rat after Chronic Cerebral Hypoperfusion
-
Kwak PA, Lim SC, Han SR, Shon YM, Kim YI
- KMID: 2287580
- J Clin Neurol.
- 2012 Dec;8(4):284-292.
- doi: 10.3988/jcn.2012.8.4.284
BACKGROUND AND PURPOSE: White-matter (WM) lesions are known to potentiate cognitive impairment in poststroke patients. The present study was designed to assess whether Ginkgo biloba extract (GB) and cilostazol, which... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Neonate with Acute Renal Failure after Maternal Treatment with Angiotensin II Receptor Blocker
-
Ra JJ, Eun HS, Lee SM, Park MS, Namgung R, Lee C, Park KI
- KMID: 2280895
- Korean J Perinatol.
- 2012 Dec;23(4):286-291.
Hypertension is common medical problem encountered during pregnancy. However medication administered for maternal hypertension may cause fetal or neonatal complications. Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker are... -
- CITED
-
- Close
- SHARE
-
- Close
- KR-31543 reduces the production of proinflammatory molecules in human endothelial cells and monocytes and attenuates atherosclerosis in mouse model
-
Choi JH, Yoo JY, Kim SO, Yoo SE, Oh GT
- KMID: 1402317
- Exp Mol Med.
- 2012 Dec;44(12):733-739.
KR-31543, (2S, 3R, 4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl) amino]-3,4-dihydro-2-dimethyoxymethyl-3-hydroxy-2-methyl-2H-1-benz opyran is a new neuroprotective agent for ischemia-reperfusion damage. It has also been reported that KR-31543 has protective effects on lipid peroxidation and H2O2-induced reactive... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetic and Pharmacodynamic Study Determines Factors Affecting Blood Pressure Response to Valsartan
-
Cho JM, Yim SV, Jin H, Sohn IS, Hwang HJ, Park CB, Jin ES, Kim CJ
- KMID: 2330957
- J Korean Soc Hypertens.
- 2012 Sep;18(3):88-96.
BACKGROUND: Valsartan is an angiotensin II receptor blocker and is used for patient with hypertension. Although response to valsartan varies each individual, there is no study about factors affecting the... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of Platelet Function Test on Platelet Responsiveness and Clinical Outcome After Coronary Stent Implantation: Platelet Responsiveness and Clinical Outcome
-
Yu LH, Kim MH, Zhang HZ, Park JS, Park TH, Kim YD, Cha KS, Han JY
- KMID: 1433857
- Korean Circ J.
- 2012 Jun;42(6):382-389.
- doi: 10.4070/kcj.2012.42.6.382
BACKGROUND AND OBJECTIVES: The aim of this study was to confirm the predictive cut-off values for P2Y12 reaction units (PRU) and aspirin reaction units (ARU) and to evaluate the clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation
-
Jung IH, Lee YH, Yoo JY, Jeong SJ, Sonn SK, Park JG, Ryu KH, Lee BY, Han HY, Lee SY, Kim DY, Lee H, Oh GT
- KMID: 1383792
- Exp Mol Med.
- 2012 May;44(5):311-318.
In this study, the synergistic effect of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone (cilostazol) and Ginkgo biloba extract (GbE) was examined in apolipoprotein E (ApoE) null mice. Co-treatment with GbE and cilostazol synergistically decreased... -
- CITED
-
- Close
- SHARE
-
- Close
- Critical Appraisal of SCAST Study
-
Kim HY
- KMID: 2288726
- Korean J Stroke.
- 2012 Apr;14(1):52-54.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Antiplatelet Therapy for Secondary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke
-
Park TH, Kim MK, Oh HG, Oh MS, Yu KH, Hong KS, Bae HJ, Kwon SU, Rha JH, Heo JH, Oh CW, Lee BC, Yoon BW
- KMID: 2288717
- Korean J Stroke.
- 2012 Apr;14(1):1-5.
Writing Committee of Korean clinical practice guidelines for secondary prevention of stroke has reviewed recent randomized controlled trials of cilostazol published after the first edition of Korean clinical practice guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- Cilostazol Decreases Ethanol-Mediated TNFalpha Expression in RAW264.7 Murine Macrophage and in Liver from Binge Drinking Mice
-
Lee YJ, Eun JR
- KMID: 2071759
- Korean J Physiol Pharmacol.
- 2012 Apr;16(2):131-138.
- doi: 10.4196/kjpp.2012.16.2.131
Alcoholic hepatitis is a leading cause of liver failure in which the increased production of tumor necrosis factor alpha (TNFalpha) plays a critical role in progression of alcoholic liver disease.... -
- CITED
-
- Close
- SHARE
-
- Close
- Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent Implantation
-
Kee WJ, Jeong MH, Jang SY, Lee MG, Park KH, Sim DS, Hong YJ, Kim JH, Ahn Y, Kang JC
- KMID: 1776253
- Korean Circ J.
- 2011 Dec;41(12):754-758.
- doi: 10.4070/kcj.2011.41.12.754
We report our experience of very late stent thrombosis (VLST) in a young male patient who underwent implantation of two paclitaxel-eluting stents (PES) six years ago. The patient was compliant... -
- CITED
-
- Close
- SHARE
-
- Close
